Technology ID

Methods of Treating Giardiasis Using FDA-Approved Compounds

Lead Inventor
Zheng, Wei (National Human Genome Research Institute (NIH/NHGRI))
Chen, Catherine (National Human Genome Research Institute (NIH/NHGRI))
Marugan, Juan (National Human Genome Research Institute (NIH/NHGRI))
Southall, Noel (National Human Genome Research Institute (NIH/NHGRI))
Austin, Christopher (National Human Genome Research Institute (NIH/NHGRI))
Herzberg, Osnat (University of Maryland)
Galkin, Andrey (University of Maryland)
Therapeutic Areas
Infectious Disease
Development Status
  • Early-stage
  • Pre-clinical
  • In vitro data available
Lead IC
This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions. Additional active compounds identified include: Acivicin, Riboflavin butyrate, BTO-1, GW9662, Dinitroph-dfgp, Deserpidine, Tetramethylthiuram disulsulfide, Disulfiram, Mitoxantrone, Ecteinascidin 743, 17-allyaminogeldanamycin, Carboquone and Nocodazole. The anti-Giardial activity of these compounds presents a cost saving opportunity for the rapid development of new, better tolerated treatments for the most prevalent human intestinal parasite infection in the United States and the world.
Commercial Applications
  • Treatment of Giardia in humans
  • Treatment of Giardia in animals - dogs and cats
Competitive Advantages
These compounds have currently been approved for human and veterinary uses of other indications which provides an opportunity to greatly reduce risk and pre-market investments both in terms of time and costs associated with development and regulatory approval for new Giardia applications including the drug resistant Giardiasis.
Licensing Contact:
Vepa, Suryanarayana